Is lurbinectedin approved for immunotherapy?
No, lurbinectedin (brand name Zepzelca) is not approved for immunotherapy. The FDA approved it in June 2020 for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy.[1] It works as an alkylating agent that binds DNA and inhibits transcription, not through immune system modulation like checkpoint inhibitors (e.g., PD-1/PD-L1 blockers).[2]
How does lurbinectedin actually work?
Lurbinectedin traps transcription factors on DNA, causing double-strand breaks and selective tumor cell death, especially in SCLC with high transcription activity. Clinical trials like the Phase 2 basket trial showed 35% overall response rate in SCLC, leading to accelerated approval later converted to full approval in 2024 based on confirmatory data.[1][3]
Is it used in combination with actual immunotherapies?
Yes, often. Standard SCLC regimens pair it with immunotherapy like atezolizumab (Tecentriq) or durvalumab (Imfinzi) post-platinum failure. The IMforte trial (NCT04626587) tests lurbinectedin plus atezolizumab as first-line maintenance, but this is investigational, not approved as immunotherapy itself.[4]
What immunotherapies are approved for SCLC instead?
For extensive-stage SCLC, first-line options include carboplatin/etoposide with PD-L1 inhibitors like atezolizumab or durvalumab, based on IMpower133 and CASPIAN trials (OS benefit of 2-3 months).[5] Lurbinectedin fills the post-chemo relapse niche but lacks immune checkpoint activity.
Any ongoing trials exploring immunotherapy angles?
Phase 3 trials like LAGOON (NCT05143260) combine lurbinectedin with irinotecan vs. topotecan for relapsed SCLC, without immunotherapy. Earlier studies (e.g., NCT02454972) tested it with doxorubicin, focusing on chemo synergy, not immune enhancement.[3]
Patent and exclusivity status
U.S. patents on lurbinectedin extend to 2031, with pediatric exclusivity to 2032. No generic or biosimilar challenges noted yet.6
[1]: FDA.gov - Zepzelca Approval Summary (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213069s009lbl.pdf)
[2]: Trigo et al., Lancet Oncol 2020 (https://pubmed.ncbi.nlm.nih.gov/32407804/)
[3]: ClinicalTrials.gov - Lurbinectedin Studies
[4]: ClinicalTrials.gov - IMforte (NCT04626587) (https://clinicaltrials.gov/study/NCT04626587)
[5]: Paz-Ares et al., Lancet 2019 (IMpower133)